Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer

Bcl-2 is overexpressed in about a half of human cancers and 50–70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powerful tools for specific gene silencing and molecular...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ibrahim Tekedereli, S Neslihan Alpay, Ugur Akar, Erkan Yuca, Cristian Ayugo-Rodriguez, He-Dong Han, Anil K Sood, Gabriel Lopez-Berestein, Bulent Ozpolat
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2013-01-01
Edice:Molecular Therapy: Nucleic Acids
Témata:
apoptosis
autophagy
Bcl-2
breast cancer
chemotherapy
estrogen receptor
gene silencing
liposome
nanoparticles
nanotherapeutics
programmed cell deathsiRNA
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2162253116301780
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky